Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

Contributed by: PR Newswire

Tags

Frontier-GSK-RNA

More Like This

Novotech Report Reveals Growth in siRNA Research: Over 150 Industry-Sponsored Clinical Trials Conducted from 2020 to 2024

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

PR Newswire associated0

Skyhawk Therapeutics Announces Strategic Collaboration with Merck to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders

PR Newswire associated0

Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI

PR Newswire associated0

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates

PR Newswire associated0

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH